semaglutide glp 1 receptor agonist Rising Demand for GLP-1 Agonists Means an Increase in Patient Questions GLP-1 Agonists For Obesity In

Mounjaro Eye Side Effects Lawsuit Overview Lawsuits filed against the manufacturer of Mounjaro, Eli Lilly and Company, allege that the company failed to warn users about the risk of blindness and other injuries associated with the use of the drug

The market has huge opportunity but is at initial stages of adoption

Figure 1 depicts the action of GLP-1 RAs on target tissues

Moreover, enhanced physician confidence and guideline support for wider therapeutic applications propel earlier adoption in a large number of healthcare facilities and payer systems, worldwide

What oral GLP-1 agonists are on the horizon

The wide use of these drugs and their adverse effects, although rare, need to be considered and calculated by patients who are using the drugs for weight